ELK1 and ovarian carcinoma: In combination, these results demonstrate that NF-κB1, c-Rel, and ELK1 bind to their respective recognition sites in the putative promoter region of miR-134 and repress its expression in paclitaxel-resistant SKOV3-TR30 ovarian cancer cells.